Targeting inflammation in heart failure with histone deacetylase inhibitors.
Cardiovascular insults such as myocardial infarction and chronic hypertension can trigger the heart to undergo a remodeling process characterized by myocyte hypertrophy, myocyte death and fibrosis, often resulting in impaired cardiac function and heart failure. Pathological cardiac remodeling is associated with inflammation, and therapeutic approaches targeting inflammatory cascades have shown promise in patients with heart failure. Small molecule histone deacetylase (HDAC) inhibitors block adverse cardiac remodeling in animal models, suggesting unforeseen potential for this class of compounds for the treatment of heart failure. In addition to their beneficial effects on myocardial cells, HDAC inhibitors have potent antiinflammatory actions. This review highlights the roles of HDACs in the heart and the potential for using HDAC inhibitors as broad-based immunomodulators for the treatment of human heart failure.
Department of Medicine, Division of Cardiology, University of Colorado Denver, Aurora, Colorado 80045-0508, USA. timothy.mckinsey@ucdenver.edu
Timothy A
TA
McKinsey
D000818:Animals; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use
D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors
Pharmacol Ther. 2009 Aug;123(2):255-78
19460403
Circulation. 2008 May 20;117(20):2670-83
18474815
Circulation. 2009 Jan 27;119(3):480-6
19171871
Nat Rev Drug Discov. 2009 Dec;8(12):969-81
19855427
Nature. 2003 Apr 17;422(6933):730-4
12700764
Nat Med. 2007 Aug;13(8):952-61
17660828
Trends Biochem Sci. 2002 Jan;27(1):40-7
11796223
Br J Pharmacol. 2010 Apr;159(7):1408-17
20180942
Gastroenterology. 2010 Feb;138(2):583-94
19879272
Mol Cell Biol. 2004 Oct;24(19):8467-76
15367668
FASEB J. 2008 Oct;22(10):3549-60
18606865
J Mol Cell Cardiol. 2008 Dec;45(6):715-23
18926829
J Mol Cell Cardiol. 2009 Dec;47(6):770-80
19729022
JAMA. 2004 Nov 17;292(19):2396-8
15547168
Annu Rev Pharmacol Toxicol. 2005;45:657-87
15822192
Heart Fail Rev. 2010 Jul;15(4):331-41
19363700
Clin Cancer Res. 2006 Aug 1;12(15):4628-35
16899611
Circ Res. 2010 Feb 5;106(2):272-84
20133912
Mol Cell Biol. 2004 Jan;24(1):306-19
14673164
Nat Med. 2007 Nov;13(11):1299-307
17922010
Cardiovasc Res. 2007 Dec 1;76(3):473-81
17884027
Am J Pathol. 2008 Jul;173(1):57-67
18535174
Curr Treat Options Cardiovasc Med. 2009 Feb;11(1):79-87
19141264
Cell. 2010 Mar 19;140(6):845-58
20303875
Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H968-77
17400721
Am J Cardiol. 2010 May 15;105(10):1371-1377.e1
20451681
Circ J. 2010 Apr;74(4):760-70
20208383
Circ Heart Fail. 2010 Jan;3(1):157-64
19880804
Circulation. 1999 Jun 29;99(25):3224-6
10385494
Front Biosci (Landmark Ed). 2009 Jun 01;14:4992-5012
19482601
Matrix Biol. 2010 Sep;29(7):602-12
20470885
JAMA. 2004 Nov 17;292(19):2350-6
15547162
Nat Med. 2007 Mar;13(3):324-31
17322895
Circulation. 2006 Jan 3;113(1):51-9
16380549
J Acquir Immune Defic Syndr. 2010 May 1;54(1):1-9
20300007
J Mol Cell Cardiol. 2010 Aug;49(2):334-8
20433848
Circulation. 2001 Apr 24;103(16):2055-9
11319194
Mol Cell Biol. 2004 Oct;24(19):8374-85
15367659
Hypertension. 2010 Sep;56(3):437-44
20679181
Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L864-70
19700647
Circulation. 2000 Dec 19;102(25):3060-7
11120695
Ann Hematol. 2010 Feb;89(2):185-90
19633847
Cancer Res. 2004 Feb 1;64(3):1079-86
14871841
Genes Dev. 2007 Jul 15;21(14):1790-802
17639084
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2870-5
14976250
J Mol Biol. 2004 Apr 16;338(1):17-31
15050820
Cell. 2002 Aug 23;110(4):479-88
12202037
Trends Cardiovasc Med. 2006 Nov;16(8):273-9
17055383
Cell Physiol Biochem. 2010;25(4-5):451-8
20332626
Circulation. 2006 Oct 24;114(17):1883-91
17060398
Circulation. 2004 Apr 6;109(13):1594-602
15023878
Nat Biotechnol. 2007 Jan;25(1):84-90
17211407
Biochem Soc Trans. 2009 Oct;37(Pt 5):1126-32
19754465
J Clin Invest. 2003 Sep;112(6):863-71
12975471
Cytokine. 1995 Aug;7(6):526-33
8580368
Circulation. 2006 Jun 6;113(22):2579-88
16735673
Nat Rev Genet. 2009 Jan;10(1):32-42
19065135
Circulation. 2003 Jul 1;107(25):3133-40
12796126
J Mol Biol. 2005 Jan 7;345(1):91-102
15567413
Cardiovasc Res. 2008 Dec 1;80(3):416-24
18697792
Arthritis Rheum. 2011 May;63(5):1452-8
21538322
N Engl J Med. 1990 Jul 26;323(4):236-41
2195340
Circulation. 2009 Jun 9;119(22):2904-12
19470887
Nat Chem Biol. 2010 Mar;6(3):238-243
20139990
Eur J Pharmacol. 2007 Oct 1;571(2-3):88-96
17628529
J Biol Chem. 2008 Apr 11;283(15):10135-46
18250163
Expert Opin Investig Drugs. 2010 Sep;19(9):1049-66
20687783
Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H2154-63
20382965
Circulation. 2010 Jun 8;121(22):2407-18
20497976
J Clin Invest. 2006 Jul;116(7):1853-64
16767219
Mol Cell. 2008 Aug 22;31(4):449-461
18722172
Ann Rheum Dis. 2010 Sep;69(9):1665-70
20498217
Exp Mol Pathol. 2009 Oct;87(2):99-104
19577564
Circ Res. 2008 Nov 21;103(11):1259-69
18849323
J Clin Oncol. 2006 Jan 1;24(1):166-73
16330674
Clin Cancer Res. 2008 Feb 1;14(3):826-32
18245545
J Biol Chem. 2003 Aug 1;278(31):28930-7
12761226
Eur J Pharmacol. 2010 Sep 10;642(1-3):28-36
20553909
J Med Chem. 2004 Oct 7;47(21):5235-43
15456267
Circulation. 2001 Feb 27;103(8):1044-7
11222463